A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
10/1999
10/26/1999	US5972698 Tryptase is expressed virtually exclusively by mast cells.
10/26/1999	US5972335 Compositions for promoting the healing of wounds or fibrotic disorders comprising at least one agent specific to either a growth factor or a protein associated therewith; antibodies
10/26/1999	US5970985 Use of hemoglobin to treat systemic inflammatory response syndrome
10/26/1999	CA2132993C Physiologically active substance
10/21/1999	WO1999053066A1 U4, a member of the hematopoietin receptor superfamily
10/21/1999	WO1999053032A1 TRANSGENIC MAMMALS EXPRESSING MUTANT GP IIIa
10/21/1999	WO1999052907A1 Azabicyclic 5ht1 receptor ligands
10/21/1999	WO1999052895A1 Amidine compounds
10/21/1999	WO1999052542A1 Use of erythropoietin for the treatment of haemochromatoses
10/21/1999	WO1999052514A2 Pharmaceutical composition and combination preparation for immunosuppressive therapy
10/21/1999	WO1999046245A3 PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL
10/21/1999	DE19827633A1 Production of N-methyl-N-(1-phenyl-2-(3-hydroxypyrrolidino)ethyl)-2,2-diphenylacetamide enantiomers, e.g. with antiinflammatory, analgesic and diuretic activity
10/21/1999	DE19816983A1 New bicyclic heteroaromatic amidine or nitrile compounds, used as thrombin inhibitors, antithrombotic agents or intermediates
10/21/1999	DE19816857A1 Novel adenosine antagonists useful in treatment of e.g. neurodegenerative, pulmonary, renal and cardiovascular disorders
10/21/1999	CA2327782A1 Azabicyclic 5ht1 receptor ligands
10/21/1999	CA2327488A1 Amidine compounds
10/21/1999	CA2327431A1 Pharmaceutical composition
10/21/1999	CA2325817A1 Transgenic mammals expressing mutant gp iiia
10/21/1999	CA2324992A1 U4, a member of the hematopoietin receptor superfamily
10/20/1999	EP0950713A2 Recombinant adenoviral vector for gene transfer
10/20/1999	EP0950661A1 Substituted tricyclics useful in sPLA2 induced diseases
10/20/1999	EP0950657A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors
10/20/1999	EP0950416A1 Preventive and/or therapeutic agent for cachexia
10/20/1999	EP0950100A1 Keratinocyte growth factor-2 (kgf-2 or fibroblast growth factor-12, fgf-12)
10/20/1999	EP0950099A1 NOVEL flt-3 RECEPTOR AGONISTS
10/20/1999	EP0950047A1 Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
10/20/1999	EP0949946A1 Biological fluid processing
10/20/1999	EP0949924A1 Use of cyanines, isocyanines and pseudoisocyanines as diuretics
10/20/1999	EP0949921A1 Thrombin inhibitors
10/20/1999	EP0787119B1 Salts of aminoalcohols and pharmaceutical formulations containing them
10/20/1999	CN1232501A Modified TIE-2 -receptor ligands
10/20/1999	CN1232398A IL-8 receptor antagonists
10/20/1999	CN1045767C Pyrazole derivs, processes for preparation thereof and pharmaceutical composition comprising same
10/19/1999	US5969125 Polynucleotideds that encode polypeptides that can be used to generate antibodies to prevent, treat, and reduce effects of disease
10/19/1999	US5968976 Gastrointestinal tract disorders
10/19/1999	US5968967 Pyrazolones derivatives
10/19/1999	US5968897 Cardiovascular disorders and blood factors
10/19/1999	US5968726 Blood substitute of aqueous solution of hydroxyethyl starch, simple sugar, dynamic buffer, sodium ions, chloride ions, magnesium ions, potassium ions, and calcium ions; with subphysiological concentrations of potassium; autoclavable
10/19/1999	US5968501 Genetically engineering, transformation
10/19/1999	US5968499 Polymeric compounds
10/17/1999	CA2269262A1 Substituted tricyclics
10/17/1999	CA2269256A1 Substituted tricyclics
10/14/1999	WO1999051741A2 Lyst protein complexes and lyst interacting proteins
10/14/1999	WO1999051732A1 Secreted proteins and polynucleotides encoding them
10/14/1999	WO1999051626A2 Template associated npy y2-receptor agonists
10/14/1999	WO1999051571A1 Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
10/14/1999	WO1999051242A1 Medicinal compositions for treating edema
10/14/1999	WO1999043809A3 Protease-activated receptor 4 and uses thereof
10/14/1999	WO1999042089A3 Use of thiadiazolo[4,3-a]pyridine derivatives
10/14/1999	CA2326759A1 Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
10/14/1999	CA2326146A1 Template associated npy y2-receptor agonists
10/14/1999	CA2325562A1 Lyst protein complexes and lyst interacting proteins
10/14/1999	CA2324984A1 Secreted proteins and polynucleotides encoding them
10/13/1999	EP0948620A2 Secreted proteins and polynucleotides encoding them
10/13/1999	EP0948539A2 Peptides and compounds that bind to a receptor
10/13/1999	EP0948525A1 Cyclic peptide derivatives
10/13/1999	EP0948496A2 Substituted pyrimidinone and pyridone compounds and methods of use
10/13/1999	EP0948342A1 MEDICAL USES OF scuPA/suPAR COMPLEX
10/13/1999	EP0948337A1 Treatment of hemoglobin containing erythrocytes with nitric oxide
10/13/1999	EP0948323A1 Protease-activated receptor 3 and uses thereof
10/13/1999	EP0948257A1 Triaryl substituted imidazoles, compositions containing such compounds and methods of use
10/13/1999	EP0579618B1 Pyridine- and imidazole-derived agents for cardiovascular diseases
10/13/1999	CN1231671A Antithrombotic azacycloalkylakanoyl peptides and pseudopeptides
10/13/1999	CN1231666A Tricyclic benzazepine vasopressin antagonists
10/13/1999	CN1231659A Stable non-hygroscopic crystalline form of N-[N-N-(4-(piperidin-4-YL) butanoyl)-N-ethylglycyl] compound
10/12/1999	US5965692 Anticoagulants for treatment of thromobosis and hypercoagulability in blood and tissues
10/12/1999	US5965580 Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them
10/12/1999	US5965564 Enantiomerically pure hydroxylated xanthine compounds
10/12/1999	US5965559 Aminoheterocyclic derivatives as antithrombotic or anticoagulant
10/12/1999	US5965533 Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
10/12/1999	US5965532 Low molecular weight, synthetic crosslinking boron compounds as an agonists or antagonists and induce association between naturally occurring receptors, t cell surface receptor
10/12/1999	US5965423 A polypeptide; diagnosis of cirrhosis, multiple sclerosis, gastrointestinal disorders, respiratory disorders, acquired immune defiency syndrome; antiarthritic/antiischemic/ antiallergens/ antiproliferactive agents
10/12/1999	US5965416 Arginyl tRNA synthetase from staphyloccus aureus
10/12/1999	US5965397 Protein factor, cytokines, lymphokines, interferons, and interleukins, and colony stimulating factors; treatment of osteoporosis, stimulating or bone growth, regeneration of nerve and brain tissue, alzheimer/huntington disease's
10/12/1999	US5965388 Isolated polynucleotides; diagnosis and treatment autoimmune diseases, tissue rejection, allergies, acquired immune deficiency disease; viricides, bactericides and fungicides; anticarcinogenic agents
10/12/1999	US5965139 Chicken infectious anemia virus vaccine
10/12/1999	CA2096851C Tissue plasminogen activator substitution variant
10/12/1999	CA2024476C Benzopyranone-.beta.-d-thioxylosides their method of preparation and their use in therapy
10/07/1999	WO1999050413A2 THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
10/07/1999	WO1999050296A1 Treatment and prevention of vascular disease
10/07/1999	WO1999050263A1 Quinolones as serine protease inhibitors
10/07/1999	WO1999050257A1 Benzoxazinones/benzothiazinones as serine protease inhibitors
10/07/1999	WO1999050255A2 Disubstituted pyrazolines and triazolines as factor xa inhibitors
10/07/1999	WO1999050254A1 Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
10/07/1999	WO1999050249A2 Pyrimidines and triazines as integrin antagonists
10/07/1999	WO1999050248A1 Pyridazinone hydrochloride compound and method for producing the same
10/07/1999	WO1999049897A1 Hemoglobin-polysaccharide conjugates
10/07/1999	WO1999049880A1 Methods for treating an ischemic disorder and improving stroke outcome
10/07/1999	WO1999043310A3 20-hete antagonists and agonists
10/07/1999	WO1999042501A3 Method for the production of polymers from n-vinyl compounds
10/07/1999	WO1999040220A3 Method of screening therapeutic agents
10/07/1999	CA2333927A1 Pyrimidines and triazines as integrin antagonists
10/07/1999	CA2326588A1 Methods for treating an ischemic disorder and improving stroke outcome
10/07/1999	CA2326506A1 Pyridazinone hydrochloride compound and method for producing the same
10/07/1999	CA2324517A1 Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily
10/07/1999	CA2324476A1 Treatment and prevention of vascular disease
10/07/1999	CA2321538A1 Disubstituted pyrazolines and triazolines as factor xa inhibitors
10/07/1999	CA2319551A1 Benzoxazinones/benzothiazinones as serine protease inhibitors
10/07/1999	CA2312953A1 Quinolones as serine protease inhibitors
10/06/1999	EP0946715A1 Modified protein c and methods of use thereof

1 ... 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 ... 671